Equity awards to Spero (NASDAQ: SPRO) director Scott Jackson
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Spero Therapeutics director Scott Thomas Jackson reported new equity awards. He received 10,000 shares of common stock in the form of restricted stock units (RSUs), each representing one share upon vesting. These RSUs vest on June 23, 2027, conditioned on his continued service.
He was also granted stock options for 20,000 shares of common stock at an exercise price of $2.15 per share, expiring on June 23, 2036. These options vest and become exercisable in full on June 23, 2027, subject to continued board service. Following the RSU award, his direct common stock holdings total 85,000 shares. These are compensation-related grants, not open-market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Jackson Scott Thomas
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 20,000 | $0.00 | -- |
| Grant/Award | Common Stock | 10,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 20,000 shares (Direct, null);
Common Stock — 85,000 shares (Direct, null)
Footnotes (1)
- Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
Key Figures
RSU grant: 10,000 shares
Stock options granted: 20,000 options
Option exercise price: $2.15 per share
+3 more
6 metrics
RSU grant
10,000 shares
Restricted stock units granted on June 23, 2026; vest June 23, 2027
Stock options granted
20,000 options
Right to buy common stock granted June 23, 2026; vest June 23, 2027
Option exercise price
$2.15 per share
Exercise price for 20,000 stock options expiring June 23, 2036
Shares held after award
85,000 shares
Total direct common stock holdings following RSU grant
Option expiration
June 23, 2036
Expiration date of stock option grant for 20,000 shares
RSU vesting date
June 23, 2027
Vest date for 10,000 RSUs, subject to continued service
Key Terms
restricted stock units ("RSUs"), Stock Option (right to buy), exercise price, vest, +1 more
5 terms
restricted stock units ("RSUs") financial
"Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of 2.1500."
exercise price financial
"conversion_or_exercise_price: "2.1500" for the stock option grant."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercisable financial
"The shares underlying this option will vest and become exercisable in full on June 23, 2027."
FAQ
What insider transaction did Spero Therapeutics (SPRO) report for Scott Thomas Jackson?
Spero Therapeutics reported that director Scott Thomas Jackson received equity awards: 10,000 restricted stock units and stock options for 20,000 shares at a $2.15 exercise price, both vesting in 2027 as part of his board compensation.
What are the terms of Scott Thomas Jackson’s RSU award from Spero Therapeutics (SPRO)?
Jackson was granted 10,000 restricted stock units, each equal to one Spero Therapeutics common share upon vesting. The RSUs vest on June 23, 2027, provided he continues serving through that date, making this a time-based compensation grant.
What are the key details of Scott Thomas Jackson’s stock option grant at Spero Therapeutics (SPRO)?
He received options for 20,000 Spero Therapeutics common shares with a $2.15 exercise price. These options fully vest and become exercisable on June 23, 2027, require continued service as a director, and expire on June 23, 2036 if not exercised earlier.
Does Scott Thomas Jackson’s Form 4 for Spero Therapeutics (SPRO) show any open-market buying or selling?
The Form 4 shows only compensation-related acquisitions: 10,000 restricted stock units and 20,000 stock options. There are no open-market purchases or sales reported, and the awards were granted at no cash cost per share on the transaction date.
When will Scott Thomas Jackson’s Spero Therapeutics (SPRO) equity awards become available to him?
Both the 10,000 restricted stock units and the 20,000 stock options are scheduled to vest on June 23, 2027. Vesting and, for options, exercisability depend on Jackson continuing to serve as a director through that vesting date.